



Influenza Vaccine
Fluzone[®] **High-Dose**
Quadrivalent

FOR ADULTS 65+

DEMONSTRATED EVIDENCE FOR FLUZONE[®] HIGH-DOSE QUADRIVALENT

FLUZONE[®] High-Dose Quadrivalent vaccine is indicated for active immunization against influenza caused by the specific strains of influenza virus contained in the vaccine in adults 65 years of age and older.¹

CONSIDERING INFLUENZA A AND B IN ADULTS 65+

Influenza A

- Influenza A is most often the predominant influenza virus subtype²
- Influenza A viruses are classified into subtypes based on two surface proteins: HA and NA. Three subtypes of HA (H1, H2, and H3) and two subtypes of NA (N1 and N2) are recognized as having caused widespread human disease³
- There is an increased burden of disease associated with influenza A in older adults³
- In this population, better protection against influenza A should be prioritized³

Influenza B

- Influenza B viruses have evolved into two antigenically distinct lineages since the mid-1980s, represented by B/Yamagata/16/88-like and B/Victoria/2/87-like viruses⁴
- Viruses from 2 influenza B lineages contribute variably to influenza illness each year³
- Over time, antigenic variation (antigenic drift) of strains occurs within an influenza A subtype or a B lineage, requiring seasonal influenza vaccines to be reformulated annually³

Adults 65+³



At a high risk of severe influenza-related complications and hospitalization

HA: Hemagglutinin; NA: Neuraminidase.

* FLUZONE® High-Dose Quadrivalent is not indicated to reduce influenza-related complications or hospitalization

FLUZONE® HIGH-DOSE QUADRIVALENT

FLUZONE® High-Dose Quadrivalent vaccine is indicated for active immunization against influenza caused by the specific strains of influenza virus contained in the vaccine in adults 65 years of age and older.¹



Includes 2 influenza A strains and 2 influenza B strains



0.7 mL **pre-filled syringe** for intramuscular injection

65+

For use in adults **65 years of age and older**

THE EFFICACY EXPERIENCE WITH FLUZONE® HIGH-DOSE (TRIVALENT) IS RELEVANT TO FLUZONE® HIGH-DOSE QUADRIVALENT SINCE BOTH VACCINES ARE MANUFACTURED ACCORDING TO THE SAME PROCESS AND HAVE OVERLAPPING COMPOSITIONS.

Superior efficacy demonstrated for FLUZONE® High-Dose (trivalent) compared to FLUZONE® (trivalent), a standard-dose influenza vaccine

PRIMARY ENDPOINT^{1*†‡}

24.2%

(attack rate 1.43% vs. 1.89%)

FLUZONE® High-Dose (trivalent) vs. FLUZONE® (trivalent)

More efficacious against lab-confirmed influenza illness caused by any viral type or subtype in adults 65+ (95% CI: 9.7–36.5)

*In a multicentre, double-blind efficacy study conducted over two influenza seasons (2011-2012 and 2012-2013), adults ≥65 years were randomized to receive either FLUZONE® High-Dose (trivalent) or standard-dose FLUZONE® (trivalent). FLUZONE® High-Dose (trivalent) contained 60 µg of HA per strain/dose while FLUZONE® (trivalent) contained 15 µg of HA per strain/dose. Per-protocol analysis set for efficacy assessments included 15,892 FLUZONE® High-Dose (trivalent) and 15,911 FLUZONE® (trivalent) recipients. Primary endpoint was occurrence of laboratory-confirmed influenza caused by any influenza viral type/subtype in association with influenza-like illness, defined as a new onset (or exacerbation) of at least one of the following respiratory symptoms: sore throat, cough, sputum production, wheezing, or difficulty breathing; concurrent with at least one of the following systemic signs or symptoms: temperature >37.2°C, chills, tiredness, headaches or myalgia. In the first year of the study, the influenza B component of the vaccine and the majority of influenza B cases were of the Victoria lineage; in the second year, the influenza B component of the vaccine and the majority of influenza B cases were of the Yamagata lineage.

†The pre-specified statistical superiority criterion for the primary endpoint (lower limit of the 2-sided 95% CI of the vaccine efficacy of FLUZONE® High-Dose (trivalent) relative to FLUZONE® (trivalent) >9.1%; p-value against $H_0: VE \leq 9.1\% = 0.022$ one-sided) was met.

‡The standard dose FLUZONE® vaccine (trivalent) is not available in Canada.

SAFETY INFORMATION

Indications and clinical use:

FLUZONE® High-Dose Quadrivalent vaccine is indicated for active immunization against influenza caused by the specific strains of influenza virus contained in the vaccine in adults 65 years of age and older.

The National Advisory Committee on Immunization (NACI) provides additional guidance on the use of the influenza vaccine in Canada. Please refer to the published Statement on Seasonal Influenza Vaccine for the current season.

Contraindications:

Should not be administered to anyone with a known systemic hypersensitivity reaction after previous administration of any influenza vaccine or to any component of the vaccine (e.g. eggs or egg products).

Relevant warnings & precautions:

- FLUZONE® High-Dose Quadrivalent is not indicated for persons less than 65 years of age.
- Syncope can occur following, or even before, any vaccination as a psychogenic response to the needle injection. Procedures should be in place to prevent falling and injury and to manage syncope.
- As with any vaccine, immunization with FLUZONE® High-Dose Quadrivalent may not protect 100% of individuals. At this time, current influenza virus vaccines are not effective against all possible influenza strains. Protection is highest against those strains of virus from which the vaccine is prepared or against closely related strains.
- Do not administer by intravascular injection. Do not administer into the buttocks.
- Postpone vaccination in case of moderate/severe febrile illness or acute disease.
- FLUZONE® High-Dose Quadrivalent should not be administered to persons suffering from coagulation disorders or on anticoagulation therapy unless potential benefits outweigh administration risk. If the decision is made to administer any product by intramuscular injection to such persons, it should be given with caution, with steps taken to avoid hematoma formation risk following injection.
- Immunogenicity may be reduced by immunosuppressive therapy or in immunocompromised individuals. It is recommended to postpone vaccination until after the immunosuppressive therapy or resolution of the immunosuppressive condition, if feasible.
- If Guillain-Barré syndrome (GBS) has occurred within 6 weeks of any previous influenza vaccination, the decision to give FLUZONE® High-Dose Quadrivalent should be based on careful consideration of potential benefits and risks.
- Local reactions at injection site such as pain, erythema, swelling, induration and bruising may occur.

For more information:

Visit <https://products.sanofi.ca/en/fluzone-hd.pdf> for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The product monograph is also available through our medical department. Call us at 1-888-621-1146.

REFERENCES

1. Product Monograph: FLUZONE® High-Dose Quadrivalent. Sanofi Pasteur. June 16, 2020.
2. Thommes, et al. Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines. *Hum Vaccin Immunother*. 2017;13(4):867-876.
3. National Advisory Committee on Immunization (NACI). Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2020–2021. Retrieved from <https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/healthy-living/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2020-2021/naci-2020-2021-seasonal-influenza-stmt-eng.pdf>.
4. National Advisory Committee on Immunization (NACI). Literature Review on Quadrivalent Influenza Vaccines. Retrieved from http://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-117-2014-eng.pdf.

FLUZONE® is a trademark of Sanofi Pasteur. Sanofi Pasteur 1755 Steeles Avenue West, Toronto, Ontario M2R 3T4
© 2021 Sanofi Pasteur Limited. All rights reserved.
DIN: 02500523
MAT-CA-2001063

SANOFI PASTEUR 

